Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Bullboard (TSXV:TLT)

View:
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Post by Oden6570on Nov 25, 2024 6:58am

My AI Bot Bart likes our chances with BTD !

Number 2 always confuses me with regards to trial results , at this point how big of an impact on % is the non optimized numbers ? Theralase Technologies Inc. is making significant progress in ...more  
156
Comment by reconsideron Nov 24, 2024 8:41pm

RE:RE:Forbes on BTD published in Nature.

Just look at IBRX. They received BTD in December '19. $1.5 to $7 in 1 month (x4.5). $13 in July '20 (x8.5). $30 in Feb '21 (x15). Had a lot to do with COVID stonking also, but never the ...more  
193
Discussion
Comment by CancerSlayeron Nov 24, 2024 5:43pm

RE:Forbes on BTD published in Nature.

A BTD is one piece (big or small) of value creation for an "investor"...this is not a speculative play for me & most on this board. Although technically this company may be considered a ...more  
239
Discussion
Comment by Sosak1on Nov 24, 2024 3:28pm

RE:Pivotal Phase 2 Trial for GBM - Berubicin

The new drug, Ziihera, could net Zymeworks more than $1 billion just in milestone payments, and millions more in royalties, upon full commercialization. Gaining the FDA’s accelerated approval ...more  
149
Discussion
Post by Eoganachton Nov 24, 2024 3:25pm

Pivotal Phase 2 Trial for GBM - Berubicin

If all goes well, in 2025 Theralase should begin a phase 1 GBM trial. An obvious question is whether or not a phase 3 trial will be required by the FDA. Maybe not... CNS Pharmaceutical's ...more  
241
Discussion
Comment by Alamir1111on Nov 24, 2024 2:12pm

RE:Forbes on BTD published in Nature.

https://search.app?link=https%3A%2F%2Fwww.biv.com%2Fnews%2Ftechnology%2Ffda-approves-cancer-drug-developed-by-bcs-zymeworks-9847508@utm_campaign=aga@utm_source=agsadl2%2Csh%2Fx%2Fgs%2Fm2%2F4
67
Discussion
Comment by Kayz88on Nov 24, 2024 12:21pm

RE:Forbes on BTD published in Nature.

I don't think it's a lifesaver, but it'll be an amazing stop gap for all the low raises. I can't access the other article but I'm curious what the market cap was of the companies ...more  
161
Discussion
Post by Dumbeldorfwhiteon Nov 24, 2024 11:43am

Forbes on BTD published in Nature.

for all those hanging their hat on BTD being some lifesaver. https://www.forbes.com/sites/frankdavid/2019/02/23/btd-event-study/
185
Discussion
Comment by Dumbeldorfwhiteon Nov 24, 2024 10:20am

RE:RE:RE:RE:1 Year ago today !

Can you make any more excuses? It has been a poorly run trial that's all there is to it. It started with not dosing the first 12 correctly which at their enrollment pace how could you fail to ...more  
102
Discussion
Comment by fecatson Nov 24, 2024 9:32am

RE:RE:RE:RE:RE:1 Year ago today !

Wildbird , I sure wish FDA would read all of your past posts . You make strong points that all of our competitors are basically terds . Love it !!
93
Discussion
Comment by Oilminerdeluxeon Nov 24, 2024 9:01am

RE:RE:RE:RE:RE:1 Year ago today !

I know nothing about what immunity Bio has in its pipeline, but I sure like that we are better than them and they have a 3.5B market cap. 
85
Discussion
Comment by wildbird1on Nov 24, 2024 8:36am

RE:RE:RE:RE:1 Year ago today !

CancerSlayer, thank's for the clarifications, people tend to forget about the difficult journey TLT had to go through to get were we are. About Anktiva (ImmunityBio). 1)Anktiva is a 14 months ...more  
225
Discussion
Comment by CancerSlayeron Nov 24, 2024 7:12am

RE:RE:RE:1 Year ago today !

I believe the pandemic, limited budget & limited number of trial sites (as well as the more gradual onboarding of US sites) significantly impacted trial speed & progress. Enrollment hit a snag ...more  
169
Discussion
Post by Oden6570on Nov 24, 2024 5:51am

I do hope we see movement on the HSV- 1 commercialization

Scope of the problem In 2020 (last available estimates), 3.8 billion people under the age of 50, or 64.2% of the global population, had HSV-1 infection (oral or genital). Most HSV-1 infections are ...more  
165
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT

Visit Facebook Visit X Visit Linked In Visit Instagram Visit Youtube



INVESTORS & MEDIA OVERVIEW FINANCIAL FILINGS PRESENTATIONS MEDIA FACT SHEETS MANAGEMENT

Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250